Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
IMGN is in the medium-term down -50% below S&P in 1 year.
Description: ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Its product candidates include IMGN853, which is in Phase I clinical trials for the treatment of ovarian cancer, endometrial cancer, and other cancers; IMGN289 that is in Phase I clinical trials for treating squamous cell carcinoma of head and neck cancer, and non-small cell lung cancer; IMGN529, which is in Phase I clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia; and IMGN779 that is in preclinical stage for treating acute myeloid leukemia. The company also develops compounds, such as AMG 172 that is in Phase I clinical trials for the treatment of clear cell renal cell carcinoma; AMG 595, which is in Phase I clinical trials for treating glioblastoma; BAY 94-9343 is in early clinical trials for the t
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||98.97%||Sales Growth - Q/Q||-76.34%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-42.42%||ROE||-95.13%||ROI|
|Current Ratio||5.22||Quick Ratio||5.1||Long Term Debt/Equity||Debt Ratio||0.38|
|Gross Margin||Operating Margin||-71.01%||Net Profit Margin||-72.15%||Dividend Payout Ratio|
|Cash From Financing Activities||1.43 M||Cash From Investing Activities||-5.03 M||Cash From Operating Activities||-26.84 M||Gross Profit|
|Net Profit||-30.47 M||Operating Profit||-25.09 M||Total Assets||313.82 M||Total Current Assets||278.11 M|
|Total Current Liabilities||35.81 M||Total Debt||Total Liabilities||278.72 M||Total Revenue||12.61 M|
|High 52 week||12.95||Low 52 week||3.94||Last close||4.83||Last change||-1.63%|
|RSI||39.32||Average true range||0.32||Beta||1.44||Volume||965.36 K|
|Simple moving average 20 days||-5.45%||Simple moving average 50 days||-5.21%||Simple moving average 200 days||-41.12%|
|Performance Week||1.47%||Performance Month||-2.23%||Performance Quart||-18.69%||Performance Half||-47.39%|
|Performance Year||-50.51%||Performance Year-to-date||0.63%||Volatility daily||4.16%||Volatility weekly||9.31%|
|Volatility monthly||19.08%||Volatility yearly||66.11%||Relative Volume||259.72%||Average Volume||2.57 M|
|New High||New Low|
2019-03-12 08:56:12 | Options Traders Expect Huge Moves in ImmunoGen IMGN Stock
2019-03-10 09:30:01 | ImmunoGen IMGN Down 50.2% Since Last Earnings Report: Can It Rebound?
2019-03-06 12:22:06 | ImmunoGen Failure Casts a Shadow on Antibody-Drug Conjugates
2019-03-06 12:05:00 | Four Biotech Stocks Setting The Standard on Wednesday
2019-03-06 10:26:03 | Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More
2019-03-04 23:38:04 | Immunogen Ovarian Cancer Drug Fails in Phase III, Stock Sinks
2019-03-04 08:06:31 | Why ImmunoGen Tanked on Friday
2019-03-02 12:48:05 | Immunogen Inc IMGN Files 10-K for the Fiscal Year Ended on December 31, 2018
2019-03-01 13:45:00 | Immunogen Tanks After Ovarian Cancer Drug Study Fails to Meet Endpoint
2019-03-01 12:13:42 | Why ImmunoGen Stock Is Crashing Today
2019-03-01 08:08:23 | Shares of Waltham drugmaker ImmunoGen crater after late-stage trial fail
2019-03-01 06:38:56 | ImmunoGen's ovarian cancer drug fails in late-stage study
2019-02-27 17:14:00 | Why ImmunoGen Tumbled 20.3% Today
2019-02-27 16:31:00 | ImmunoGen Announces Multiple Presentations at AACR Annual Meeting
2019-02-22 07:40:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Apple, United Continental, ImmunoGen, CymaBay Therapeutics, Granite Construction, and Flotek Industries — New Research Emphasizes Economic Growth
2019-02-21 08:00:00 | Healthcare Companies Investors are Watching
2019-02-18 14:19:27 | How ImmunoGen, Inc. NASDAQ:IMGN Could Add Value To Your Portfolio
2019-02-12 15:58:00 | ImmunoGen Still Waiting to Take Its Leap "Forward"
2019-02-11 09:29:02 | ImmunoGen IMGN Beats on Earnings & Sales in Q4, Shares Up
2019-02-11 08:53:01 | Options Traders Expect Huge Moves in ImmunoGen IMGN Stock
2019-02-08 21:35:52 | ImmunoGen IMGN Q4 2018 Earnings Conference Call Transcript
2019-02-08 21:20:10 | Edited Transcript of IMGN earnings conference call or presentation 8-Feb-19 1:00pm GMT
2019-02-08 07:45:12 | ImmunoGen IMGN Reports Q4 Loss, Tops Revenue Estimates
2019-02-08 06:47:20 | ImmunoGen: 4Q Earnings Snapshot
2019-02-08 06:30:00 | ImmunoGen Reports Recent Progress and 2018 Operating Results
2019-02-06 18:35:00 | Why ImmunoGen Jumped Almost 14% Today
2019-02-01 10:30:03 | Earnings Preview: ImmunoGen IMGN Q4 Earnings Expected to Decline
2019-01-24 16:30:00 | ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results
2019-01-18 15:00:19 | Have Insiders Been Selling ImmunoGen, Inc. NASDAQ:IMGN Shares This Year?
2019-01-08 16:01:00 | ImmunoGen Announces Sale of Residual Kadcyla Royalties
2019-01-07 17:20:00 | Why ImmunoGen Jumped Today
2018-12-26 16:18:00 | Why ImmunoGen Shot Up 13% Today
2018-12-17 21:52:44 | Hedge Funds Are Betting On ImmunoGen, Inc. IMGN
2018-12-06 14:49:07 | Roche's Kadcyla Halves Death Risk in Breast Cancer Study
2018-12-02 09:30:02 | ImmunoGen IMGN Down 7.2% Since Last Earnings Report: Can It Rebound?
2018-11-26 16:47:15 | Former Aveo exec resigns as ImmunoGen CFO after fraud verdict
2018-11-26 16:01:00 | ImmunoGen Announces Resignation of Chief Financial Officer
2018-11-25 09:41:17 | The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings
2018-11-21 11:23:32 | Former Aveo CFO misled biotech's investors, jury finds
2018-11-20 08:31:01 | Are Options Traders Betting on a Big Move in ImmunoGen IMGN Stock?
2018-11-14 11:35:00 | Healthcare Stocks with Turnaround Potential
2018-11-12 07:32:00 | How Has Cara Therapeutics’ 2018 Performance Shaken Out?